Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) Saphnelo (anifrolumab-fnia) has been approved in the USA for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
The approval by the Food and Drug Administration was based on efficacy and safety data from the Saphnelo clinical development program including two TULIP Phase III trials and the MUSE Phase II trial. In these trials, more patients treated with the drug experienced a reduction in overall disease activity across organ systems, including skin and joints, and achieved sustained reduction in oral corticosteroid (OCS) use compared to placebo, with both groups receiving standard therapy.
This marks the first regulatory approval for a type I interferon (type I IFN) receptor antagonist and the only new treatment approved for SLE in more than 10 years. It also comes 10 years after GlaxoSmithKline (LSE: GSK) gained FDA approval of its SLE treatment Benlysta (belimumab) in 2011, breaking almost 50 years of stagnation in this field.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze